secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K/A
Filed at:   2022-07-20T23:59:59+00:00
Accession:  0000875045-22-000023
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q2 GAAP EPS $7.24, revenue $2.59B down 7% YoY; raises FY2022 guidance
----------------------------------------------------------------------------

- Revenue $2,589M (-7% YoY); GAAP EPS $7.24, Non-GAAP EPS $5.25.
- MS revenue $1,719M (-4% YoY); SPINRAZA $431M (-14%); Biosimilars $194M.
- FDA Priority Review for lecanemab in early Alzheimer's; decision by Jan 6, 2023; Phase 3 data expected Fall 2022.
- Positive Phase 3 for zuranolone in PPD; joint US filing for MDD and PPD expected H2 2022.
- Company raises full year 2022 financial guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504522000023/0000875045-22-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504522000023/biib-20220720.htm
  HTML page:      https://secwatch.observer/filing/0000875045-22-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer